Login
$NVAX
$8.07 +$0.01 (0.12%) After hours

$NVAX 8-K/A SEC Filings

Filed On Filing
02 Nov 2023 8-K/A: Submission of Matters to a Vote of Security Holders

Consistent with the recommendation of the Company’s Board of Directors (the “Board”) as set forth in the Company’s proxy statement with respect to the 2023 Annual Meeting, a majority of votes at the 2023 Annual Meeting were cast in favor...

09 Dec 2022 8-K/A: Departure/Election of Directors or Officers; Compensation

On November 1, 2022, Novavax, Inc. (the “Company”) filed a Current Report on Form 8-K reporting that the Company’s Board of Directors (the “Board”) had appointed Richard J. Rodgers to the Board. At the time of the filing, the Board had n...

16 Dec 2020 8-K/A: Departure/Election of Directors or Officers; Compensation

On November 3, 2020, Novavax, Inc. (the “Company”) filed a Current Report on Form 8-K reporting that the Company’s Board of Directors (the “Board”) had appointed Gregg H. Alton to the Board. On December 9, 2020, the Company filed a Curre...

10 Aug 2020 8-K/A: Completion of Acquisition or Disposition of Assets

We have audited the accompanying financial statements of Praha Vaccines a.s., which comprise the balance sheets as of December 31, 2019 and December 31, 2018 and the related statements of operations, changes in stockholders’ equity and c...

07 May 2014 8-K/A: Changes in Registrant's Certifying Accountant

The Audit Committee (the “Audit Committee”) of the Board of Directors of Novavax, Inc. (the “Company”) has completed a competitive process to select the Company’s independent registered public accounting firm for the fiscal year ending D...

02 May 2014 8-K/A: Changes in Registrant's Certifying Accountant

We have read Item 4.01 of Form 8-K of Novavax, Inc. dated April 30, 2014, and agree with the statements concerning our Firm contained therein.

09 Jul 2007 8-K/A: Entry into a Material Definitive Agreement

ROCKVILLE, MD (July 9, 2007) – Novavax, Inc. (Nasdaq: NVAX) announced today that is has signed a non-exclusive, worldwide license agreement with Wyeth Holdings Corporation, a subsidiary of Wyeth (NYSE: WYE), to obtain rights to a family ...

14 Nov 2006 8-K/A: Financial Statements and Exhibits

MALVERN, PA (November 14, 2006) — /PRNewswire-FirstCall/ — Novavax Inc. (NASDAQ: NVAX), today announced its financial results for the third quarter ended September 30, 2006. Novavax reported a net loss of $5.0 million ($0.08 per share) f...

09 Aug 2005 8-K/A: Results of Operations and Financial Condition

FOR IMMEDIATE RELEASENASDAQ symbol: NVAXNOVAVAX ANNOUNCES SECOND QUARTER RESULTS MALVERN, PA., August 9, 2005 – Novavax, Inc. (Nasdaq: NVAX), a specialty biopharmaceutical company, today announced its second quarter financial and operati...

14 Mar 2005 8-K/A: Departure/Election of Directors or Officers; Compensation

(b) On March 9, 2005, Ronald H. Walker informed the Board of Directors that he would retire from the Board of Directors, effective as of the 2005 Annual Meeting of Stockholders to be held May 4, 2005, and would therefore not stand for re...

04 Nov 2004 8-K/A: Departure/Election of Directors or Officers; Compensation

MALVERN, PA, OCTOBER 28, 2004 — NOVAVAX, INC. (NASDAQ: NVAX) today announced the appointment of Susan B. Bayh to the Company’s Board of Directors. Bayh, 44, is a new addition to the Board and brings the number of independent directors to...

23 Mar 2001 8-K/A: Financial Statements and Exhibits

We hereby consent to the use in this current report on Form 8-K/A of Novavax, Inc. of our report dated March 1, 2001, relating to the Statements of Revenues and Direct Operating Expenses of the AVC Product Line of King Pharmaceuticals, I...

21 Dec 2000 8-K/A: Completion of Acquisition or Disposition of Assets

COMPANY CONTACTS: John A. Spears President & CEO NOVAVAX, INC. 301-854-3900

18 Dec 2000 8-K/A: Financial Statements and Exhibits

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-22685, No. 333-77609 and No. 333-32142) and Form S-8 (No. 333-77611 and No. 333-46000) of Novavax, Inc. of our report dated October 2...

18 Oct 1999 8-K/A: Financial Statements and Exhibits

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support